close

Agreements

Date: 2011-09-13

Type of information: R&D agreement

Compound:

Company: Novalix (France) Fondation Jerome Lejeune (France)

Therapeutic area: Genetic diseases

Type agreement:

R&D

Action mechanism:

Disease:

Details:

NovAliX has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune. NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine beta-­synthase (CBS). Indeed inhibition of CBS over-expression has been associated with restoration of cognitive impairment in animal models afflicted with trisomy.

Financial terms:

Latest news:

Is general: Yes